Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthocell Ltd ( (AU:OCC) ) has provided an announcement.
Orthocell Limited announced a webinar to discuss the first US surgical use of Remplir™ and the progress of its rollout in the US. This development marks a significant step in Orthocell’s expansion strategy, potentially enhancing its market position in regenerative medicine and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for tissue reconstruction in dental and orthopedic applications, as well as products like Remplir™ for peripheral nerve reconstruction and SmrtGraft™ for tendon repair. The company is actively expanding its market presence in the US and other countries.
Average Trading Volume: 1,294,812
Technical Sentiment Signal: Buy
Current Market Cap: A$266.5M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.